Chia-Jui Yen

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo et al. · The Lancet Oncology · 2015 · 845 citations · Full text

Medicine, Oncology, Pharmacology +9

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen et al. · Nature Medicine · 2021 · 403 citations

Medicine, Oncology, Pharmacology +6

The Crosstalk of mTOR/S6K1 and Hedgehog Pathways

Yan Wang, Qingqing Ding, Chia-Jui Yen et al. · Cancer Cell · 2012 · 349 citations · Full text

Life Sciences, Biology, Molecular Biology +10

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer et al. · Cancer Discovery · 2019 · 250 citations · Full text

Medicine, Oncology, Pharmacology +17

Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer

Qingqing Ding, Longfei Huo, Jer-Yen Yang et al. · Cancer Research · 2008 · 194 citations

Life Sciences, Cell Biology, Oncology +17